Cargando…
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
OBJECTIVE: The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy. METHODS: Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who...
Autores principales: | Kitada, Munehiro, Tsuda, Shin-ichi, Konishi, Kazunori, Takeda-Watanabe, Ai, Fujii, Mizue, Kanasaki, Keizo, Nishizawa, Makoto, Nakagawa, Atsushi, Koya, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Open Diabetes Research & Care
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530236/ https://www.ncbi.nlm.nih.gov/pubmed/28761658 http://dx.doi.org/10.1136/bmjdrc-2017-000391 |
Ejemplares similares
-
Associations of Renal Vascular Resistance With Albuminuria and Other Macroangiopathy in Type 2 Diabetic Patients
por: Hamano, Kumiko, et al.
Publicado: (2008) -
Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes
por: Oshima, Megumi, et al.
Publicado: (2021) -
Serum isthmin-1 levels are positively and independently correlated with albuminuria in patients with type 2 diabetes mellitus
por: Wang, Chuan, et al.
Publicado: (2022) -
Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes
por: Wakasugi, Satomi, et al.
Publicado: (2021) -
Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)